日本医保加收政策对髋部骨折术后再骨折风险及二级预防的影响
该研究基于日本2019至2023年医保理赔数据,采用中断时间序列分析评估2022年4月实施的髋部骨折术后二级预防医保加收政策。结果显示,政策实施12个月后1年再骨折累积风险绝对降低1.02个百分点,90天内DXA评估和120天内启动抗骨质疏松药物的累积概率分别绝对提高41.37和22.83个百分点,但1年治疗持续性绝对下降6.76个百分点。
要点
- 政策与1年再骨折累积风险降低1.02个百分点相关(95%CI -1.44至-0.60)。
- 政策与90天内DXA评估概率提高41.37个百分点相关(95%CI 40.21至42.54)。
- 政策与1年治疗持续性降低6.76个百分点相关(95%CI -10.04至-3.49)。
核心结论
- 该医保加收政策与髋部骨折术后1年再骨折累积风险降低、早期DXA评估和抗骨质疏松药物启动概率提高相关,但与1年治疗持续性改善无关。
研究设计与样本
- 基于日本2019至2023年纵向医保理赔数据的人群基础中断时间序列分析,纳入≥50岁新发且手术治疗的髋部骨折成人,干预为2022年4月1日实施的政策。
主要发现
- 政策实施12个月后,1年再骨折累积风险的绝对效应为-1.02个百分点(95%CI -1.44至-0.60)。
- 90天DXA评估累积概率的绝对效应为41.37个百分点(95%CI 40.21至42.54)。
- 120天启动抗骨质疏松药物累积概率的绝对效应为22.83个百分点(95%CI 21.70至23.95)。
- 1年骨折后治疗持续性的绝对效应为-6.76个百分点(95%CI -10.04至-3.49)。
临床怎么用
- 政策实施后应关注早期DXA评估和药物启动的落实,同时需制定支持长期随访和再 engagement 的策略以维持治疗持续性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: In Japan, a national reimbursement add-on for secondary fracture prevention after hip fracture surgery, implemented on April 1, 2022, was associated with lower 1-year refracture risk and higher early uptake of post-fracture DXA assessment within 90 days and anti-osteoporosis medication initiation within 120 days, but not with improved 1-year post-fracture treatment persistence. PURPOSE: To assess whether the Japanese national reimbursement add-on policy for preventing secondary fracture after hip fracture surgery, introduced in April 2022, was associated with actual changes in refracture risk and key secondary fracture prevention care processes after hip fracture surgery. METHODS: We conducted a population-based interrupted time-series analysis using longitudinal health insurance claims data collected in Japan between 2019 and 2023. Participants were adults aged ≥ 50 years with newly identified and surgically treated hip fracture. The intervention was implementation of the policy on 1 April 2022. Outcome measures were absolute changes 12 months after policy implementation in the 1-year cumulative risk of first refracture, 90-day cumulative probability of receiving dual-energy X-ray absorptiometry (DXA) assessment, 120-day cumulative probability of initiating anti-osteoporosis medication, and 1-year post-fracture treatment persistence. RESULTS: Twelve months after policy implementation, the absolute effect on the 1-year cumulative risk of refracture in the hip fracture series was - 1.02 percentage points (95% confidence interval, - 1.44 to - 0.60). The absolute effects on early care processes were 41.37 percentage points (40.21 to 42.54) for DXA assessment and 22.83 percentage points (21.70 to 23.95) for the initiation of anti-osteoporosis medication. The absolute effect on 1-year post-fracture treatment persistence was - 6.76 percentage points (- 10.04 to - 3.49). CONCLUSIONS: The reimbursement add-on policy for secondary fracture prevention after hip fracture surgery was associated with a lower 1-year cumulative refracture risk and a higher cumulative probability of receiving DXA assessment and initiating anti-osteoporosis medication, but not with improved 1-year post-fracture treatment persistence. Strategies supporting sustained follow-up and reengagement may be needed.
引用
- Hatano M, Saito T, Kimura Y, et al. Impact of a national reimbursement add-on policy on refracture risk and secondary fracture prevention after hip fracture in Japan: a population-based interrupted time series analysis. Osteoporos Int. 2026. PMID: 42008165. doi:10.1007/s00198-026-08023-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。